WO2016183371A8 - Methods for the treatment or prevention of ischemic tissue damage - Google Patents

Methods for the treatment or prevention of ischemic tissue damage Download PDF

Info

Publication number
WO2016183371A8
WO2016183371A8 PCT/US2016/032194 US2016032194W WO2016183371A8 WO 2016183371 A8 WO2016183371 A8 WO 2016183371A8 US 2016032194 W US2016032194 W US 2016032194W WO 2016183371 A8 WO2016183371 A8 WO 2016183371A8
Authority
WO
WIPO (PCT)
Prior art keywords
tissue damage
subject
ischemic tissue
methods
prevention
Prior art date
Application number
PCT/US2016/032194
Other languages
French (fr)
Other versions
WO2016183371A1 (en
Inventor
Dennis M. Klinman
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services
Publication of WO2016183371A1 publication Critical patent/WO2016183371A1/en
Publication of WO2016183371A8 publication Critical patent/WO2016183371A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

Methods are disclosed for inhibiting or reducing ischemic tissue damage in a subject. These methods include selecting a subject having ischemic tissue damage or at risk of developing ischemic tissue damage and administering to the subject a therapeutically effective amount of an imidazoquinoline compound. In some embodiments, the method also includes administering to the subject a therapeutically effective amount of an immunostimulatory composition comprising an immunostimulatory oligodeoxynucleotide and a pharmaceutically acceptable carrier prior to administering the imidazoquinoline compound to the subject. The immunostimulatory composition includes either a D-type CpG oligodeoxynucleotide or a K-type CpG oligodeoxynucleotide.
PCT/US2016/032194 2015-05-13 2016-05-12 Methods for the treatment or prevention of ischemic tissue damage WO2016183371A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160836P 2015-05-13 2015-05-13
US62/160,836 2015-05-13

Publications (2)

Publication Number Publication Date
WO2016183371A1 WO2016183371A1 (en) 2016-11-17
WO2016183371A8 true WO2016183371A8 (en) 2016-12-08

Family

ID=56093001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/032194 WO2016183371A1 (en) 2015-05-13 2016-05-12 Methods for the treatment or prevention of ischemic tissue damage

Country Status (1)

Country Link
WO (1) WO2016183371A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3135161A1 (en) * 2019-02-01 2020-08-06 Canwell Biotech Limited Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (en) 1981-10-23 1992-04-29 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and methods of making same
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0388434A4 (en) 1987-11-18 1990-12-19 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Differential delivery of therapeutic agents across the blood brain barrier
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
DE60131430T2 (en) 2000-01-14 2008-10-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services OLIGODE OXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE REACTION
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8043622B2 (en) 2002-10-08 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
PL1653959T3 (en) 2003-08-14 2015-10-30 3M Innovative Properties Co Lipid-modified immune response modifiers
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007030580A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20100130425A1 (en) * 2005-09-09 2010-05-27 Oregon Health & Science University Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
US20090306190A1 (en) * 2005-09-09 2009-12-10 Mary Stenzel-Poore Neuroprotectants
MX359517B (en) 2010-08-17 2018-10-01 3M Innovative Properties Company Star Lipidated immune response modifier compound compositions, formulations, and methods.
AU2012261959B2 (en) 2011-06-03 2015-12-03 Solventum Intellectual Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
US9803678B2 (en) 2014-08-11 2017-10-31 Akko Fastener Inc. Arc weld stud having a forming thread

Also Published As

Publication number Publication date
WO2016183371A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
WO2016109684A3 (en) Derivatives and methods of treating hepatitis b infections
WO2016137235A3 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
WO2012139081A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2017059385A8 (en) 11,13-modified saxitoxins for the treatment of pain
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
MX2018003930A (en) Human plasma kallikrein inhibitors.
WO2016010788A8 (en) Polyketal particles including a cpg oligodeoxynucleotide for the treatment of lung cancer
WO2016127123A3 (en) Compounds and methods for preventing or treating sensory hair cell death
WO2016181220A3 (en) Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
EP3856172A4 (en) Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
EP3810755A4 (en) Hiv treatment compositions and methods
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2019003039A (en) Extended relief dosage form.
MX2022003945A (en) Method for treating hiv with cabotegravir and rilpivirine.
WO2016183371A8 (en) Methods for the treatment or prevention of ischemic tissue damage
MX2018001684A (en) Method of wound healing.
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
EP3600306A4 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
IL281080A (en) Compositions comprising a selenite-containing compound and a pharmaceutically acceptable acid for treating human papillomavirus infections
MX2017014301A (en) Compositions and methods for the treatment or prevention of pulmonary hypertension.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16726242

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16726242

Country of ref document: EP

Kind code of ref document: A1